Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig L Slingluff

Showing results (61-70 of 225) with videos related to

Pageof 23
Sort By:
Clinical Trials (London, England)|March 30, 2024
Applications of the partial-order continual reassessment method in the early development of treatment combinationsNolan A Wages, Patrick M Dillon, Craig A Portell, et al.
Vaccines|February 26, 2026
Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine AdjuvantsEmily G Ashkani, Anna M Dickinson, Walter C Olson, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 11, 2021
Immunotyping and Quantification of Melanoma Tumor-Infiltrating LymphocytesMax O Meneveau, Zeyad T Sahli, Kevin T Lynch, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 30, 2012
Research incentive program for clinical surgical faculty associated with increases in research productivityAnneke T Schroen, Monika J Thielen, Florence E Turrentine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopesSara J Adair, Tiffany M Carr, Mitsú J Fink, et al.
Vaccine|February 3, 2009
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapiesKimberly A Chianese-Bullock, Sarah T Lewis, Nicholas E Sherman, et al.
Cancer Research|June 4, 2008
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2Kerrington R Molhoek, Heinrich Griesemann, Jianfen Shu, et al.
International Journal of Cancer|March 14, 2015
TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10Ileana S Mauldin, Ena Wang, Donna H Deacon, et al.
Ebiomedicine|June 23, 2016
Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanomaMouadh Benamar, Fadila Guessous, Kangping Du, et al.
Melanoma Research|September 28, 2022
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumabNicole L Edmonds, Sarah E Flores, Adela Mahmutovic, et al.
Pageof 23

Showing results (61-70 of 225) with videos related to

Sort By:
Pageof 23
Clinical Trials (London, England)|March 30, 2024
Applications of the partial-order continual reassessment method in the early development of treatment combinationsNolan A Wages, Patrick M Dillon, Craig A Portell, et al.
Vaccines|February 26, 2026
Evaluation of Antibodies Induced by Melanoma Helper Peptide Vaccine and Their Modulation by Vaccine AdjuvantsEmily G Ashkani, Anna M Dickinson, Walter C Olson, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 11, 2021
Immunotyping and Quantification of Melanoma Tumor-Infiltrating LymphocytesMax O Meneveau, Zeyad T Sahli, Kevin T Lynch, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 30, 2012
Research incentive program for clinical surgical faculty associated with increases in research productivityAnneke T Schroen, Monika J Thielen, Florence E Turrentine, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopesSara J Adair, Tiffany M Carr, Mitsú J Fink, et al.
Vaccine|February 3, 2009
Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapiesKimberly A Chianese-Bullock, Sarah T Lewis, Nicholas E Sherman, et al.
Cancer Research|June 4, 2008
Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2Kerrington R Molhoek, Heinrich Griesemann, Jianfen Shu, et al.
International Journal of Cancer|March 14, 2015
TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10Ileana S Mauldin, Ena Wang, Donna H Deacon, et al.
Ebiomedicine|June 23, 2016
Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanomaMouadh Benamar, Fadila Guessous, Kangping Du, et al.
Melanoma Research|September 28, 2022
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumabNicole L Edmonds, Sarah E Flores, Adela Mahmutovic, et al.
Pageof 23